Portal Vein Thrombosis in Liver Cirrhosis. Part 1: Epidemiology, Pathogenesis, Clinic, Diag-nosis, Impact on Prognosis

   Portal vein thrombosis is the most common thrombotic complication in patients with liver cirrhosis, especially in cases of severe forms. The pathogenesis is multifactorial in nature, it determined by a change in the balance between the coagulation and anticoagulation systems. Thrombosis is often asymptomatic and is accidentally detected, although it can be complicated by varicose bleeding, intestinal ischemia, and portal biliopathy. Ultrasound Doppler examination is a screening method, as an alternative, computed tomography and magnetic resonance imaging are used. The review highlights data on epidemiology, risk factors, clinical features, and diagnosis of portal vein thrombosis in patients with liver cirrhosis. The data on the effect of portal vein thrombosis on the progression of liver cirrhosis and the survival of patients, including after liver transplantation, are presented.

1. de Franchis R., Bosch J., Garcia-Tsao G. et al. Baveno VII — Renewing consensus in portal hypertension. J. Hepatol. 2022; 76 (4): 959-974. doi: 10.1016/j.jhep.2021.12.022

2. EASL Clinical Practice Guidelines: Vascular diseases of the liver. J. Hepatol. 2016; 64 (1): 179-202. doi: 10.1016/j.jhep.2015.07.040

3. Northup P. G., Garcia-Pagan J. C., Garcia-Tsao G. et al. Vascular liver disorders, portal vein thrombosis, and procedural bleeding in patients with liver disease: 2020 Practice Guidance by the American Association for the Study of Liver Diseases. Hepatology. 2021; 73 (1): 366-413. doi: 10.1002/hep.31646

4. Simonetto D. A., Singal A. K., Garcia-Tsao G. et al. ACG Clinical Guide-line: disorders of the hepatic and mesenteric circulation. Am. J. Gastroenterol. 2020; 115 (1): 18-40. doi: 10.14309/ajg.0000000000000486

5. Ogren M., Bergqvist D., Bjorck M. et al. Portal vein thrombosis: prevalence, patient characteristics and lifetime risk: a population study based on 23,796 consecutive autopsies. World J. Gastroenterol. 2006; 12 (13): 2115-2119. doi: 10.3748/wjg.v12.i13.2115

6. Nadinskaia M. Yu., Kodzoeva Kh. B., Gulyaeva K. A. et al. Risk factors of portal vein thrombosis in patients with different child–pugh classes liver cirrhosis. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2023; 33 (2): 45-59. doi: 10.22416/1382-4376-2023-33-2-45-59 [in Russian]

7. Francoz C., Valla D., Durand F. Portal vein thrombosis, cirrhosis, and liver transplantation. J. Hepatol. 2012; 57 (1): 203-212. doi: 10.1016/j.jhep.2011.12.034

8. Rodriguez-Castro K. I., Porte R. J., Nadal E. et al. Management of non-neoplastic portal vein thrombosis in the setting of liver transplantation : a systematic review. Transplantation. 2012; 94 (11): 1145-1153. doi: 10.1097/TP.0b013e31826e8e53

9. Pan J., Wang L., Gao F. et al. Epidemiology of portal vein thrombosis in liver cirrhosis : a systemic review and meta-analysis. Eur. J. Intern. Med. 2022; 104: 21-32. doi: 10.1016/j.ejim.2022.05.032

10. Cool J., Rosenblatt R., Kumar S. et al. Portal vein thrombosis prevalence and associated mortality in cirrhosis in a nationally representative inpatient cohort. J. Gastroenterol. Hepatol. 2019; 34 (6): 1088-1092. doi: 10.1111/jgh.14501

11. Ferreira N. C., Marinho R. T., Cortez-Pinto H. et al. Incidence, predictive factors and clinical significance of development of portal vein thrombosis in cirrhosis: a prospective study. Liver Int. 2019; 39 (8): 1459-1467. doi: 10.1111/liv.14121

12. Nery F., Chevret S., Condat B. et al. Causes and consequences of portal vein thrombosis in 1243 patients with cirrhosis: results of a longitudinal study. Hepatology. 2015; 61 (2): 660-667. doi: 10.1002/hep.27546

13. Noronha Ferreira C., Marinho R. T., Cortez-Pinto H. et al. Incidence, predictive factors and clinical significance of development of portal vein thrombosis in cirrhosis: A prospective study. Liver Int. 2019; 39 (8): 1459-1467. doi: 10.1111/liv.14121

14. Turon F., Driever E. G., Baiges A. et al. Predicting portal thrombosis in cirrhosis: A prospective study of clinical, ultrasonographic and hemostatic factors. J. Hepatol. 2021; 75 (6): 1367-1376. doi: 10.1016/j.jhep.2021.07.020

15. Violi F., Corazza G. R., Caldwell S. H. et al. Incidence and recurrence of portal vein thrombosis in cirrhotic patients. Thromb. Haemost. 2019; 119 (3): 496-499. doi: 10.1055/s-0038-1676981

16. Maruyama H., Okugawa H., Takahashi M. et al. De novo portal vein thrombosis in virus-related cirrhosis: predictive factors and long-term outcomes. Am. J. Gastroenterol. 2013; 108 (4): 568-574. doi: 10.1038/ajg.2012.452

17. Harding D. J., Perera M. T., Chen F. et al. Portal vein thrombosis in cirrhosis: controversies and latest developments. World J. Gastroenterol. 2015; 21 (22): 6769-6784. doi: 10.3748/wjg.v21.i22.6769

18. Shukla A., Giri S. Portal vein thrombosis in cirrhosis. J. Clin. Exp. Hepatol. 2022; 12: 965-979. doi: 10.1016/j.jceh.2021.11.003

19. Stine J. G., Shah N. L., Argo C. K. et al. Increased risk of portal vein thrombosis in patients with cirrhosis due to nonalcoholic steatohepatitis. Liver Transplant. 2015; 21: 1016-1021. doi: 10.1002/lt.24134

20. Odriozola A., Puente Á., Cuadrado A. et al. Portal vein thrombosis in the setting of cirrhosis: a comprehensive review. J. Clin. Med. 2022; 11: 6435. doi: 10.3390/jcm11216435

21. Anton A., Campreciós G., Pérez-Campuzano V. et al. The Pathophysiology of portal vein thrombosis in cirrhosis: getting deeper into virchow’s triad. J. Clin. Med. 2022; 11 (3): 800. doi: 10.3390/jcm11030800

22. Zocco M. A., Di S. E., De C. R. et al. Thrombotic risk factors in patients with liver cirrhosis: correlation with MELD scoring system and portal vein thrombosis development. J. Hepatol. 2009; 51 (4): 682-689. doi: 10.1016/j.jhep.2009.03.013

23. Stine J. G., Wang J., Shah P. M., Argo C. K., Intagliata N. et al. Decreased portal vein velocity is predictive of the development of portal vein thrombosis: A matched case-control study. Liver Int. 2018; 38 (1): 94-101. doi: 10.1111/liv.13500

24. Dong G., Huang X. Q., Zhu Y. L. et al. Increased portal vein diameter is predictive of portal vein thrombosis development in patients with liver cirrhosis. Ann. Transl. Med. 2021; 9 (4): 289. doi: 10.21037/atm-20-4912

25. Xu X., Xu S., Primignani M. et al. Nonselective b-blockers may progress the thrombosis of portal venous system in cirrhotic patients: a retrospective observational study. Adv. Ther. 2020; 37 (4): 1452-1463. doi: 10.1007/s12325-020-01250-z

26. EASL Clinical Practice Guidelines on prevention and management of bleeding and thrombosis in patients with cirrhosis. J. Hepatol. 2022; 76 (5): 1151-1184. doi: 10.1016/j.jhep.2021.09.003

27. Turco L., de Raucourt E., Valla D. C. et al. Anticoagulation in the cirrhotic patient. JHEP Rep. 2019; 1 (3): 227-239. doi: 10.1016/j.jhepr.2019.02.006

28. Blasi A., Patel V. C., Adelmeijer J. et al. Mixed fibrinolytic phenotypes in decompensated cirrhosis and acute-on-chronic liver failure with hypofibrinolysis in those with complications and poor survival. Hepatology. 2020; 71 (4): 1381-1390. doi: 10.1002/hep.30915

29. Lebreton A., Sinegre T., Lecompte T. et al. Thrombin generation and cirrhosis: state of the art and perspectives. Semin. Thromb. Hemost. 2020; 46 (6): 693-703. doi: 10.1055/s-0040-1715102

30. Raparelli V., Basili S., Carnevale R. et al. Low-grade endotoxemia and platelet activation in cirrhosis. Hepatology. 2017; 65 (2): 571-581. doi: 10.1002/hep.28853

31. Omer Sultan M., Farooque U., Inam Khan M. et al. Frequency of venous thromboembolism in patients with liver cirrhosis. Cureus. 2020; 12 (8): e9594. doi: 10.7759/cureus.9594

32. Barba R., Gonzalvez-Gasch A., Joya Seijo D. et al. Venous thromboembolism in patients with liver diseases. J. Thromb. Haemost. 2018; 16 (10): 2003-2007. doi: 10.1111/jth.14255

33. Ambrosino P., Tarantino L., Di Minno G. et al. The risk of venous thromboembolism in patients with cirrhosis. A systematic review and meta-analysis. Thromb. Haemost. 2017; 117 (1): 139-148. doi: 10.1160/TH16-06-0450

34. Enger C., Forssen U. M., Bennett D. et al. Thromboembolic events among patients with hepatitis C virus infection and cirrhosis: a matched-cohort study. Adv. Ther. 2014; 31 (8): 891-903. doi: 10.1007/s12325-014-0138-4

35. Jepsen P., Tapper E. B., Deleuran T. et al. Risk and outcome of venous and arterial thrombosis in patients with cirrhosis: a Danish nationwide cohort study. Hepatology. 2021; 74 (5): 2725-2734. doi: 10.1002/hep.32019

36. Praktiknjo M., Trebicka J., Carnevale R. et al. VonWillebrand and factor VIII portosystemic circulation gradient in cirrhosis: implications for portal vein thrombosis. Clin. Transl. Gastroenterol. 2020; 11 (2): e00123. doi: 10.14309/ctg.0000000000000123

37. Ren W., Zhang J., Chen Y. et al. Evaluation of coagulation, fibrinolysis and endothelial biomarkers in cirrhotic patients with or without portal venous thrombosis. Clin. Appl Thromb. Hemost. 2020; 26: 1076029620982666.

38. Zanetto A., Pelizzaro F., Campello E. et al. Severity of systemic inflammation is the main predictor of ACLF and bleeding in patients with acutely decompensated cirrhosis. J. Hepatol. 2023; 78 (2): 301-311. doi: 10.1016/j.jhep.2022.09.005

39. Quan X., Ye X., Qian S. et al. Portal vein thrombosis associates with high platelet-fibrin clot strength and platelet activation in decompensated cirrhosis: A retrospective study. Dig. Liver Dis. 2023; 55 (5): 629-636. doi: 10.1016/j.dld.2022.09.019

40. Sacco M., Tardugno M., Lancellotti S. et al. ADAMTS-13/von Willebrand factor ratio: A prognostic biomarker for portavein thrombosis in compensated cirrhosis. A prospective observational study. Dig. Liver Dis. 2022; 54 (12): 1672-1680. doi: 10.1016/j.dld.2022.06.004

41. Zanetto A., Campello E., Burra P. et al. Increased platelet ratio in patients with decompensated cirrhosis indicates higher risk of portal vein thrombosis. Liver Int. 2023; 43 (1): 155-159. doi: 10.1111/liv.15435

42. Dudov T. R., Baysaeva L. S., Yagoda A. V., Koroy P. V. Risk factors for portal vein thrombosis in liver cirrhosis. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2022; 31 (5. 59): 32. [in Russian]

43. Pasta L., Pasta F., D’Amico M. PAI-1 4G-4G, MTHFR 677TT, V Leiden 506Q, and prothrombin 20210A in splanchnic vein thrombosis: analysis of individual patient data from three prospective studies. J. Clin. Exp. Hepatol. 2016; 6 (1): 10-14. doi: 10.1016/j.jceh.2015.11.002

44. Fortea J. I., Carrera I. G., Puente Á. et al. Portal thrombosis in cirrhosis: role of thrombophilic disorders. J. Clin. Med. 2020; 9 (9): 2822. doi: 10.3390/jcm9092822

45. Ma S. D., Wang J., Bezinover D. et al. Inherited thrombophilia and portal vein thrombosis in cirrhosis : A systematic review and meta-analysis. Res. Pract. Thromb. Haemost. 2019; 3 (4): 658-667. doi: 10.1002/rth2.12253

46. Amitrano L., Guardascione M. A., Ames P. R. et al. Increased plasma prothrombin concentration in cirrhotic patients with portal vein thrombosis and prothrombin G20210A mutation. Thromb. Haemost. 2006; 95 (2): 221-223. doi: 10.1160/TH05-08-0555

47. Colucci G., Tsakiris D. A. Thrombophilia screening revisited: An issue of personalized medicine. J. Thromb. Thrombolysis. 2020; 49 (4): 618-629. doi: 10.1007/s11239-020-02090-y

48. Delgado M. G., Seijo S., Yepes I. et al. Efficacy and safety of anticoagulation on patients with cirrhosis and portal vein thrombosis. Clin. Gastroenterol. Hepatol. 2012; 10 (7): 776-783. doi: 10.1016/j.cgh.2012.01.012

49. Werner K. T., Sando S., Carey E. J. et al. Portal vein thrombosis in patients with end stage liver disease awaiting liver transplantation: outcome of anticoagulation. Dig. Dis. Sci. 2013; 58 (6): 1776-1780. doi: 10.1007/s10620-012-2548-y

50. Mehta G., Gustot T., Mookerjee R. P. et al. Inflammation and portal hypertension — the undiscovered country. J. Hepatol. 2014; 61 (1): 155-163. doi: 10.1016/j.jhep.2014.03.014

51. Villa E., Cammà C., Marietta M. et al. Enoxaparin prevents portal vein thrombosis and liver decompensation in patients with advanced cirrhosis. Gastroenterology. 2012; 143 (5): 1253-1260. doi: 10.1053/j.gastro.2012.07.018

52. Francoz C., Belghiti J., Vilgrain V. et al. Splanchnic vein thrombosis in candidates for liver transplantation: usefulness of screening and anticoagulation. Gut. 2005; 54 (5): 691-697. doi: 10.1136/gut.2004.042796

53. Zanetto A., Campello E., Pelizzaro F. et al. Haemostatic alterations in patients with cirrhosis and hepatocellular carcinoma: Laboratory evidence and clinical implications. Liver Int. 2022; 42 (6): 1229-1240. doi: 10.1111/liv.15183

54. Amitrano L., Guardascione M. A., Scaglione M. et al. Splanchnic vein thrombosis and variceal rebleeding in patients with cirrhosis. Eur. J. Gastroenterol. Hepatol. 2012; 24 (12): 1381-1385. doi: 10.1097/MEG.0b013e328357d5d4

55. Zhang Y., Xu B.-Y., Wang X.-B. et al. Prevalence and clinical significance of portal vein thrombosis in patients with cirrhosis and acute decompensation. Clin. Gastroenterol. Hepatol. 2020; 18 (11): 2564-2572. doi: 10.1016/j.cgh.2020.02.037

56. D’Amico G., de Franchis R. Upper digestive bleeding in cirrhosis. Post-therapeutic outcome and prognostic indicators. Hepatology. 2003; 38 (3): 599-612. doi: 10.1053/jhep.2003.50385

57. Harki J., Plompen E. P., van Noord D. et al. Gastrointestinal ischaemia in patients with portal vein thrombosis: a prospective cohort study. Gastrointest. Endosc. 2016; 83 (3): 627-636. doi: 10.1016/j.gie.2015.07.013

58. Luca A., Caruso S., Milazzo M. et al. Natural course of extrahepatic nonmalignant partial portal vein thrombosis in patients with cirrhosis. Radiology. 2012; 265 (1): 124-132. doi: 10.1148/radiol.12112236

59. Suárez V., Puerta A., Santos L. F. et al. Portal hypertensive biliopathy: A single center experience and literature review. World J. Hepatol. 2013; 5 (3): 137-144. doi: 10.4254/wjh.v5.i3.137

60. Bach A. M., Hann L. E., K. Brown T. et al. Portal vein evaluation with US: comparison to angiography combined with CT arterial portography. Radiology. 1996; 201 (1): 149-154. doi: 10.1148/radiology.201.1.8816536.

61. Sherman C. B., Behr S., Dodge J. L. et al. Distinguishing tumor from bland portal vein thrombus in liver transplant candidates with hepatocellular carcinoma: the A-VENA criteria. Liver Transplant. 2019; 25 (2): 207-216. doi: 10.1002/lt.25345

62. Zanetto A., Garcia-Tsao G. Some answers and more questions about portal vein thrombosis in patients with decompensated cirrhosis. Clin. Gastroenterol. Hepatol. 2020; 18 (11): 2432-2434. doi: 10.1016/j.cgh.2020.04.004

63. Berry K., Taylor J., Liou I. W. et al. Portal vein thrombosis is not associated with increased mortality among patients with cirrhosis. Clin. Gastroenterol. Hepatol. 2015; 13 (3): 585-593. doi: 10.1016/j.cgh.2014.10.010

64. Stine J. G., Shah P. M., Cornella S. L. et al. Portal vein thrombosis, mortality and hepatic decompensation in patients with cirrhosis: a meta-analysis. World J. Hepatol. 2015; 7 (27): 2774-2780. doi: 10.4254/wjh.v7.i27.2774

65. Xian J., Tang Y., Shao H. et al. Effect of portal vein thrombosis on the prognosis of patients with cirrhosis without a liver transplant : a systematic review and meta-analysis. Medicine. 2021; 100 (16): e25439. doi: 10.1097/MD.0000000000025439

66. Qi X., Dai J., Yang M. et al. Association between portal vein thrombosis and survival in non-liver-transplant patients with liver cirrhosis : a systematic review of the literature. Gastroenterol. Res. Pract. 2015; 2015: 480842. doi: 10.1155/2015/480842

67. Zanetto A., Rodriguez-Kastro K. I., Germani G. et al. Mortality in liver transplant recipients with portal vein thrombosis — an updated meta-analysis. Transpl. Int. 2018; 31 (12): 1318-1329. doi: 10.1111/tri.13353

68. Dell’Era A., Iannuzzi F., Fabris F. M. et al. Impact of portal vein thrombosis on the efficacy of endoscopic variceal band ligation. Dig. Liver Dis. 2014; 46 (2): 152-156. doi: 10.1016/j.dld.2013.08.138

69. Bhangui P., Lim C., Levesque E. et al. Novel classification of non-malignant portal vein thrombosis: A guide to surgical decision-making during liver transplantation. J. Hepatol. 2019; 71 (5): 1038-1050. doi: 10.1016/j.jhep.2019.08.012

70. Ghabril M., Agarwal S., Lacerda M. et al. Portal vein thrombosis is a risk factor for poor early outcomes after liver transplantation: analysis of risk factors and outcomes for portal vein thrombosis in waitlisted patients. Transplantation. 2016; 100 (1): 126-133. doi: 10.1097/TP.0000000000000785

71. Chen H., Turon F., Hernandez-Gea V. et al. Nontumoral portal vein thrombosis in patients awaiting liver transplantation. Liver Transpl. 2016; 22 (3): 352-365. doi: 10.1002/lt.24387

72. Englesbe M. J., Schaubel D. E., Cai S., Guidinger M. K. Portal vein thrombosis and liver transplant survival benefit. Liver Transpl. 2010; 16 (8): 999-1005. doi: 10.1002/lt.22105

73. Hibi T., Nishida S., Levi D. M. et al. When and why portal vein thrombosis matters in liver transplantation: a critical audit of 174 cases. Ann. Surg. 2014; 259 (4): 760-766. doi: 10.1097/SLA.0000000000000252

74. Sringeri R. Incidental portal vein thrombosis: does it impact the surgical outcomes following liver transplantation? Liver Transpl. 2013; 19: S289.

75. Ravaioli M., Zanello M., Grazi G. L. et al. Portal vein thrombosis and liver transplantation: evolution during 10 years of experience at the University of Bologna. Ann. Surg. 2011; 253 (2): 378-384. doi: 10.1097/SLA.0b013e318206818b